Cardior Announces First Patient Dosed in Phase 2 Study — Hadean Ventures Home Portfolio Team…
Continue Reading-
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis — Hadean…
Continue Reading -
Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension
Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute…
Continue Reading -
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro...
Continue Reading -
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333…
Continue Reading -
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA — Hadean Ventures…
Continue Reading -
Alex Therapeutics raises €3.5M in oversubscribed financing round
Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…
Continue Reading -
ALEX THERAPEUTICS
Alex Therapeutics is a digital therapeutics (DTx) company based in Stockholm...
Continue Reading -
TARGED
TargED Biopharmaceuticals (“TargED”), is a private biotechnology company...
Continue Reading -
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
Continue Reading